The effect of vilazodone on sexual function during the treatment of major depressive disorder

Journal of Sexual Medicine

Volumn 10, Issue 10, 2013, Pages 2465-2476

  Clayton, Anita H ^a   Kennedy, Sidney H ^b   Edwards, John B ^c   Gallipoli, Susan ^d   Reed, Carol R ^d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c FOREST RESEARCH INSTITUTE   (United States)

^d Clinical Data Inc   (United States)

Author keywords

Antidepressant; Decreased Sexual Desire; Major Depressive Disorder; Selective Serotonin Reuptake Inhibitor; Sexual Function; Vilazodone

Indexed keywords

PLACEBO; VILAZODONE;

ADULT; AGED; ARTICLE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EXPERIENCE; FEMALE; FOOD; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; UNITED STATES;

ANTIDEPRESSANT; DECREASED SEXUAL DESIRE; MAJOR DEPRESSIVE DISORDER; SELECTIVE SEROTONIN REUPTAKE INHIBITOR; SEXUAL FUNCTION; VILAZODONE;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BENZOFURANS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PIPERAZINES; PREVALENCE; QUESTIONNAIRES; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885928296     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12004     Document Type: Article

References (41)

1. Chen KC, Yeh TL, Lee IH, Chen PS, Huang HC, Yang YK, Shen WW, Lu RB. Age, gender, depression, and sexual dysfunction in Taiwan. J Sex Med 2009;6:3056-62.
2. Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol 2009;29:157-64.
3. Kennedy SH, Dickens SE, Eisfeld BS, Bagby RM. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord 1999;56:201-8.
4. Yang JC. Functional neuroanatomy in depressed patients with sexual dysfunction: Blood oxygenation level dependent functional MR imaging. Korean J Radiol 2004;5:87-95.
5. Yang JC, Park K, Eun SJ, Lee MS, Yoon JS, Shin IS, Kim YK, Chung TW, Kang HK, Jeong GW. Assessment of cerebrocortical areas associated with sexual arousal in depressive women using functional MR imaging. J Sex Med 2008;5:602-9.
6. Clayton AH, McGarvey EL, Clavet GJ, Piazza L. Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacol Bull 1997;33:747-53.
7. Williams VS, Baldwin DS, Hogue SL, Fehnel SE, Hollis KA, Edin HM. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: A cross-sectional patient survey. J Clin Psychiatry 2006;67:204-10.
8. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, Manber R. The Arizona Sexual Experience Scale (ASEX): Reliability and validity. J Sex Marital Ther 2000;26:25-40.
9. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KI, Donahue RM, Jamerson BD, Metz A. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-66.
10. Clayton A, Keller A, McGarvey EL. Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord 2006;91:27-32.
11. Matuszczyk JV, Larsson K, Eriksson E. Subchronic administration of fluoxetine impairs estrous behavior in intact female rats. Neuropsychopharmacology 1998;19:492-8.
12. Hull EM, Muschamp JW, Sato S. Dopamine and serotonin: Influences on male sexual behavior. Physiol Behav 2004;83:291-307.
13. Alcantara AG. A possible dopaminergic mechanism in the serotonergic antidepressant-induced sexual dysfunctions. J Sex Marital Ther 1999;25:125-9.
14. Clayton AH. The pathophysiology of hypoactive sexual desire disorder in women. Int J Gynaecol Obstet 2010;110:7-11.
15. Pfaus JG. Pathways of sexual desire. J Sex Med 2009;6:1506-33.
16. Sukoff Rizzo SJ, Pulicicchio C, Malberg JE, Andree TH, Stack GP, Hughes ZA, Schechter LE, Rosenzweig-Lipson S. 5-HT(1A) receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats. Int J Neuropsychopharmacol 2009;12:1045-53.
17. Montejo A, Majadas S, Rizvi SJ, Kennedy SH. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol 2011;26:537-42.
18. Ashton AK, Jamerson BD, Weinstein WL, Wagoner C. Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey. Curr Ther Res 2005;66:96-106.
19. Bull SA, Hunkeler EM, Lee JY, Rowland CR, Williamson TE, Schwab JR, Hurt SW. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 2002;36:578-84.
20. Keltner NL, McAfee KM, Taylor CL. Mechanisms and treatments of SSRI-induced sexual dysfunction. Perspect Psychiatr Care 2002;38:111-6.
21. Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 2006;67(6 suppl):33-7.
22. Landen M, Hogberg P, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. J Clin Psychiatry 2005;66:100-6.
23. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001;62(3 suppl):10-21.
24. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Calcedo A, Carrasco JL, Ciudad J, Daniel E, De la Gandara J, Derecho J, Franco M, Gomez MJ, Macias JA, Martin T, Perez V, Sanchez JM, Sanchez S, Vicens E. SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176-94.
25. Dawson LA, Watson JM. Vilazodone: A 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther 2009;15:107-17.
26. Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, Middlemiss DN, Dawson LA. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 2005;510:49-57.
27. Rickels K, Athanasiou M, Reed C. Vilazodone, a novel, dual-acting antidepressant: Current status, future promise, and potential for individualized treatment of depression. Personalized Med 2009;6:216-24.
28. Forest Laboratories, Inc. Viibryd [prescribing information]. St. Louis, MO: Forest Pharmaceuticals, Inc.; January 2011.
29. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003;53:193-203.
30. Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: A randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:326-33.
31. Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, Whalen H, Reed CR. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry 2011;72:441-7.
32. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition, text revision. Washington, DC: American Psychiatric Association; 2000.
33. Robinson DS, Kajdasz DK, Gallipoli S, Whalen H, Wamil A, Reed CR. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol 2011;31:643-6.
34. Keller A, McGarvey EL, Clayton AH. Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). J Sex Marital Ther 2006;32:43-52.
35. Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 2007;4:917-29.
36. Cohen J. Statistical power analysis for the behavioral sciences. 2nd edition. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
37. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis. J Clin Psychopharmacol 2009;29:259-66.
38. Baldwin DS, Cooper JA, Huusom AK, Hindmarch I. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 2006;21:159-69.
39. Clayton AH, Kornstein SG, Rosas G, Guico-Pabia C, Tourian KA. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr 2009;14:183-95.
40. Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F, Watkin JG, Detke MJ. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005;66:686-92.
41. Montejo AL, Perahia DG, Spann ME, Wang F, Walker DJ, Yang CR, Detke MJ. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder. J Sex Med 2011;8:773-82.